chitosan has been researched along with Bowel Diseases, Inflammatory in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (42.31) | 24.3611 |
| 2020's | 15 (57.69) | 2.80 |
| Authors | Studies |
|---|---|
| Jin, M; Li, X; Lu, C; Lu, X; Rao, Y; Yu, C; Yu, M; Zhao, Q; Zhu, Z | 1 |
| Jain, P; Kulkarni, N; Shindikar, A; Suryawanshi, P; Thorat, N | 1 |
| He, H; Hu, K; Qiao, J; Wang, F; Yuan, X; Zhang, H | 1 |
| Bai, X; Feng, Z; Gu, P; Jiao, L; Liu, Z; Mao, N; Peng, S; Wang, D; Yang, Y; Zhu, T | 1 |
| Choudhury, SR; Guchhait, P; Gupta, S; Karmakar, S; Mohanbhai, SJ; Sardoiwala, MN; Sharma, SS; Shrimali, N | 1 |
| Fang, S; Feng, J; Gao, F; Lan, M; Lv, Y; Ren, M; Wang, Y; Yao, M; Zhao, Y | 1 |
| Abdalla, M; Chi, Z; Hamouda, HI; Liu, C; Shabana, S; Sharaf, M | 1 |
| Ouyang, Y; Wang, S; Zhao, J | 1 |
| Cerea, M; Dubuquoy, C; Dubuquoy, L; Foppoli, A; Gazzaniga, A; Maroni, A; Moutaharrik, S; Neut, C; Palugan, L; Siepmann, F; Siepmann, J | 1 |
| Hetjens, L; Li, H; Li, X; Pich, A; Shi, X; Wolter, N | 1 |
| Aghaz, F; Alvandi, H; Arkan, E; Hosseini, O; Kahrizi, D; Naseriyeh, T; Nowroozi, G; Shamsi, A | 1 |
| Chen, Z; Feng, Y; Han, B; Leng, Y; Luo, X; Song, H; Yang, J | 1 |
| Fu, Y; Hu, J; Hu, S; Hu, Y; Kang, L; Yang, X; Zhang, S | 1 |
| Choudhury, SR; Karmakar, S; Sardoiwala, MN; Sharma, SS; Soni, JM | 1 |
| Lakshmanan, P; Newton, AMJ | 1 |
| Cosco, D; Costa, N; Francardi, M; Fresta, M; Molinaro, R; Palma, E; Paolino, D | 1 |
| Dhar, KL; Jain, N; Rajkumari, A; Sareen, R | 1 |
| Azuma, K; Imagawa, T; Itoh, N; Kiyose, M; Kurozumi, S; Minami, S; Murahata, Y; Okamoto, Y; Osaki, T; Sato, K; Tsuka, T | 1 |
| Bai, X; Duan, H; Gao, C; Liu, M; Lü, S; Qin, H; Wei, Y; Wu, X | 1 |
| Cui, YL; Gao, LN; Wang, GF; Wang, QS; Zhou, J | 1 |
| Kumar, J; Newton, AMJ | 1 |
| Bai, X; De-Ying, C; Feng, W; Li-Fang, F; Min, B; Min, Q; Qing, D; Wei, H; Yong-Zhen, C | 1 |
| Bando, Y; Kawashima, Y; Morishita, R; Samura, S; Tahara, K; Tsuji, K; Tsujimoto, H; Tsukada, Y; Yamamoto, H | 1 |
| Chatsudthipong, V; Muanprasat, C; Pichyangkura, R; Soodvilai, S; Yousef, M | 1 |
| Brayden, DJ; Coco, R; Jérôme, C; Plapied, L; Pourcelle, V; Préat, V; Schneider, YJ | 1 |
| Dhar, KL; Jain, N; Sareen, R | 1 |
2 review(s) available for chitosan and Bowel Diseases, Inflammatory
| Article | Year |
|---|---|
Advances in the colon-targeted chitosan based multiunit drug delivery systems for the treatment of inflammatory bowel disease.
Topics: Chitosan; Chronic Disease; Colon; Drug Carriers; Drug Delivery Systems; Humans; Inflammatory Bowel Diseases; Polymers | 2022 |
Multifunctional hydrogels based on chitosan, hyaluronic acid and other biological macromolecules for the treatment of inflammatory bowel disease: A review.
Topics: Chitosan; Drug Delivery Systems; Humans; Hyaluronic Acid; Hydrogels; Inflammatory Bowel Diseases | 2023 |
24 other study(ies) available for chitosan and Bowel Diseases, Inflammatory
| Article | Year |
|---|---|
Oral delivery of infliximab using nano-in-microparticles for the treatment of inflammatory bowel disease.
Topics: Administration, Oral; Alginates; Animals; Chitosan; Colitis; Drug Delivery Systems; Female; HT29 Cells; Humans; Inflammation; Inflammatory Bowel Diseases; Infliximab; Intestinal Mucosa; Mice; Mice, Inbred C57BL; Nanoparticles; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha | 2021 |
Pharmacological mechanisms of chitotriose as a redox regulator in the treatment of rat inflammatory bowel disease.
Topics: Animals; Chitosan; Inflammation; Inflammatory Bowel Diseases; Oxidation-Reduction; Oxidative Stress; Rats; Signal Transduction; Trisaccharides | 2022 |
Chitosan-modified Phellinus igniarius polysaccharide PLGA nanoparticles ameliorated inflammatory bowel disease.
Topics: Anti-Inflammatory Agents; Chitosan; Humans; Inflammatory Bowel Diseases; Nanoparticles; Phellinus; Polysaccharides | 2022 |
Colon targeted chitosan-melatonin nanotherapy for preclinical Inflammatory Bowel Disease.
Topics: Animals; Anti-Inflammatory Agents; Chitosan; Colitis, Ulcerative; Inflammatory Bowel Diseases; Melatonin; Mice | 2022 |
XA pH-Responsive and Colitis-Targeted Nanoparticle Loaded with Shikonin for the Oral Treatment of Inflammatory Bowel Disease in Mice.
Topics: Animals; Chitosan; Colitis; Colon; Cytokines; Hydrogen-Ion Concentration; Inflammatory Bowel Diseases; Mice; Nanoparticles | 2022 |
Multifunctional nanoparticles based on marine polysaccharides for apremilast delivery to inflammatory macrophages: Preparation, targeting ability, and uptake mechanism.
Topics: Caco-2 Cells; Chitosan; Delayed-Action Preparations; Drug Carriers; Drug Delivery Systems; Humans; Inflammatory Bowel Diseases; Macrophages; Mannose; Multifunctional Nanoparticles; Nanoparticles; Polysaccharides | 2022 |
In vitro and in vivo evaluation of a pH-, microbiota- and time-based oral delivery platform for colonic release.
Topics: Animals; Chitosan; Colon; Drug Delivery Systems; Hydrogen-Ion Concentration; Inflammatory Bowel Diseases; Mesalamine; Pectins; Rats; Solubility; Tablets | 2023 |
Charge-reversible and biodegradable chitosan-based microgels for lysozyme-triggered release of vancomycin.
Topics: Chitosan; Drug Delivery Systems; Inflammatory Bowel Diseases; Microgels; Muramidase; Vancomycin | 2023 |
Glycyrrhizic acid delivery system Chitosan-coated liposome as an adhesive anti-inflammation.
Topics: Adhesives; Anti-Inflammatory Agents; Chitosan; Glycyrrhizic Acid; Humans; Inflammatory Bowel Diseases; Liposomes; Particle Size | 2023 |
Encapsulation of Escherichia coli strain Nissle 1917 in a chitosan-alginate matrix by combining layer-by-layer assembly with CaCl
Topics: Alginates; Animals; Anti-Inflammatory Agents; Calcium Chloride; Chitosan; Colitis; Female; Inflammatory Bowel Diseases; Male; Particle Size; Pentobarbital; Probiotics; Rats; Rats, Sprague-Dawley; Surface Properties | 2020 |
Carboxymethyl chitosan microspheres loaded hyaluronic acid/gelatin hydrogels for controlled drug delivery and the treatment of inflammatory bowel disease.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Chitosan; Colitis; Colon; Curcumin; Drug Carriers; Drug Delivery Systems; Drug Liberation; Gelatin; Hyaluronic Acid; Hydrogels; Hydrogen-Ion Concentration; Inflammatory Bowel Diseases; Interleukin-6; Macrophages; Mice; Microscopy, Electron, Scanning; Microspheres; Rheology; Spectroscopy, Fourier Transform Infrared; Tumor Necrosis Factor-alpha; X-Ray Diffraction | 2021 |
Melatonin-loaded chitosan nanoparticles endows nitric oxide synthase 2 mediated anti-inflammatory activity in inflammatory bowel disease model.
Topics: Anti-Inflammatory Agents; Chitosan; Humans; Inflammatory Bowel Diseases; Melatonin; Nanoparticles; Nitric Oxide; Nitric Oxide Synthase Type II; Tissue Distribution | 2021 |
Comparative Efficacy of Chitosan, Pectin Based Mesalamine Colon Targeted Drug Delivery Systems on TNBS-induced IBD Model Rats.
Topics: Animals; Anti-Inflammatory Agents; Chitosan; Colon; Disease Models, Animal; Drug Delivery Systems; Humans; Inflammatory Bowel Diseases; Mesalamine; Pectins; Rats; Rats, Wistar; Reactive Oxygen Species; Trinitrobenzenesulfonic Acid; Ulcer | 2020 |
Improvement of the therapeutic treatment of inflammatory bowel diseases following rectal administration of mesalazine-loaded chitosan microparticles vs Asamax
Topics: Administration, Rectal; Animals; Anti-Inflammatory Agents, Non-Steroidal; Caco-2 Cells; Cell Survival; Chitosan; Colitis; Dextran Sulfate; Humans; Inflammatory Bowel Diseases; Mesalamine; Mice; Microspheres; Random Allocation; Treatment Outcome | 2019 |
pH triggered delivery of curcumin from Eudragit-coated chitosan microspheres for inflammatory bowel disease: characterization and pharmacodynamic evaluation.
Topics: Acetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chemistry, Pharmaceutical; Chitosan; Cross-Linking Reagents; Curcumin; Drug Delivery Systems; Excipients; Hydrogen-Ion Concentration; Inflammatory Bowel Diseases; Mice; Microspheres; Polymethacrylic Acids; Tissue Distribution | 2016 |
Anti-inflammatory effects of orally administered glucosamine oligomer in an experimental model of inflammatory bowel disease.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Body Weight; Chitin; Chitosan; Colon; Cytokines; Disease Models, Animal; Female; Inflammatory Bowel Diseases; Intestinal Mucosa; Mice; Mice, Inbred C57BL; NF-kappa B; Oligosaccharides; Organ Size; Survival Analysis | 2015 |
Mucoadhesive microparticulates based on polysaccharide for target dual drug delivery of 5-aminosalicylic acid and curcumin to inflamed colon.
Topics: Animals; Chitosan; Colitis; Colon; Curcumin; Drug Carriers; Inflammatory Bowel Diseases; Mesalamine; Polymethacrylic Acids; Rats | 2016 |
Colon targeted oral drug delivery system based on alginate-chitosan microspheres loaded with icariin in the treatment of ulcerative colitis.
Topics: Alginates; Animals; Biological Availability; Chitosan; Colitis, Ulcerative; Colon; Delayed-Action Preparations; Drug Carriers; Drug Delivery Systems; Flavonoids; Glucuronic Acid; Hexuronic Acids; Inflammation; Inflammatory Bowel Diseases; Intestinal Mucosa; Male; Microspheres; Rats; Rats, Sprague-Dawley; Solubility; Trinitrobenzenesulfonic Acid | 2016 |
Rifaximin - Chitosan Nanoparticles for Inflammatory Bowel Disease (IBD).
Topics: Animals; Chitosan; Drug Delivery Systems; Drug Design; Drug Liberation; Drug Stability; Gastrointestinal Agents; Humans; Hydrogen-Ion Concentration; Inflammatory Bowel Diseases; Microscopy, Electron, Transmission; Nanoparticles; Particle Size; Patents as Topic; Rats; Rifamycins; Rifaximin; Solubility; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction | 2017 |
Chitosan/Kollicoat SR 30D film-coated pellets of aminosalicylates for colonic drug delivery.
Topics: Aminosalicylic Acids; Animals; Chitosan; Chromatography, High Pressure Liquid; Colon; Drug Carriers; Drug Compounding; Inflammatory Bowel Diseases; Male; Microscopy, Electron, Scanning; Polyvinyls; Rats; Solubility; Surface Properties; Tablets, Enteric-Coated; Tissue Distribution | 2010 |
Oral nuclear factor-κB decoy oligonucleotides delivery system with chitosan modified poly(D,L-lactide-co-glycolide) nanospheres for inflammatory bowel disease.
Topics: Animals; Chitosan; Drug Carriers; Inflammatory Bowel Diseases; Lactic Acid; Male; Nanospheres; NF-kappa B; Oligonucleotides; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Wistar | 2011 |
Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: therapeutic efficacy and possible mechanisms of action.
Topics: Acetic Acid; Acute Disease; Administration, Oral; Animals; Anti-Inflammatory Agents; Apoptosis; Cell Line; Chitosan; Chronic Disease; Colitis; Colon; Dextran Sulfate; Disease Models, Animal; Dose-Response Relationship, Drug; Down-Regulation; Gastrointestinal Agents; Humans; Inflammation Mediators; Inflammatory Bowel Diseases; Interleukin-6; Intestinal Mucosa; Male; Mice; Mice, Inbred ICR; NF-kappa B; Oxidative Stress; Permeability; Reactive Oxygen Species; Signal Transduction; Time Factors; Tumor Necrosis Factor-alpha | 2012 |
Drug delivery to inflamed colon by nanoparticles: comparison of different strategies.
Topics: Animals; Caco-2 Cells; Chitosan; Colitis; Cytokines; Dextran Sulfate; Drug Carriers; Ethylene Oxide; Female; Humans; Inflammatory Bowel Diseases; Intestinal Absorption; Lactic Acid; Lactones; Mannose; Mice; Mice, Inbred C57BL; Nanoparticles; Ovalbumin; Polyethylene Glycols; Polyglactin 910; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymethacrylic Acids | 2013 |
Development of colon specific microspheres of flurbiprofen for inflammatory bowel disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Calorimetry, Differential Scanning; Chitosan; Colon; Flurbiprofen; Inflammatory Bowel Diseases; Microspheres; Polymethacrylic Acids; X-Ray Diffraction | 2013 |